10:19 AM EDT, 09/17/2024 (MT Newswires) -- INmune Bio ( INMB ) said Tuesday that additional analysis from its AD02 phase 2 trial for Alzheimer's disease showed "exceptional performance" of the Early AD/MCI Alzheimer's Cognitive Composite, or EMACC, measure.

The analysis revealed a "highly significant" correlation between baseline scores on EMACC and the Clinical Dementia Rating-Sum of Boxes, or CDR-SB, validating EMACC's role in accurately assessing cognitive changes, the company said.

INmune said these results affirm EMACC's potential as a primary endpoint in Alzheimer's trials, offering precise measurement of cognitive function in early Alzheimer's disease patients.

Shares of the company rose more than 2% in recent trading activity.

Price: 5.50, Change: +0.12, Percent Change: +2.14